Anti-C/EBPβ antibody, Rat monoclonal

Monoclonal Anti-C/EBPβ (rat IgG2a isotype) is derived from the hybridoma 7H5 produced by the fusion of mouse myeloma cells (SP2) and splenocytes from rat immunized with a mouse C/EBPβ fusion protein. CCAAT/enhancer binding proteins β (C/EBPβ) belongs to the highly conserved family of C/EBP transcription factors. It possesses a C-terminal basic region-leucine zipper (bZIP) domain, which is essential for DNA binding. C/EBPβ has two central regulatory domains (RDs), RD1 and RD2.

mouse C/EBPβ fusion protein

Monoclonal Anti-C/EBPβ antibody produced in rat has been used in immunoblotting and immunocytochemistry.

CCAAT/enhancer binding proteins β (C/EBPβ) exhibits plasticity with respect to various transcriptional activities it takes part in. It regulates IL-6 (interleukin-6) and IL-6-induced expression of the cytokines IL-1, IL-8, tumor necrosis factor-α (TNFα) and granulocyte colony-stimulating factor (G-CSF). C/EBPβ modulates acute phase response proteins such as α1-acid glycoprotein, α2-microglobulin and C-reactive protein. It is implicated in the development of the mammary gland and , in cell proliferation. C/EBPβ regulates survival in liver and in response to injuries and hormones in lungs. It plays a role in human breast tumorigenesis.

Solution in 0.01M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.